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Kathryn B. Garber1,*Population-Based Longitudinal Study of Autism
in Sweden
In the largest study of its kind, Sandin et al. estimated her-
itability and familial risk of autism and autism spectrum
disorder via a population-based Swedish sample. The
sample totaled more than two million individuals who
were born in Sweden between 1982 and 2006 and followed
longitudinally through 2009. Because of a healthcare
system with equal access, a mandatory developmental
assessment of all 4-year-old children, and a country-wide,
population-based register that allowed the researchers to
connect family members, this study avoided many of the
ascertainment-bias issues that could have skewed data
from similar studies. The authors were also able to assess
risk of autism on the basis of family relationships that
ranged from twins to siblings to first cousins. The heri-
tability estimated for autism spectrum disorder on the basis
of these data was 0.5, substantially lower than what has
been estimated by some prior studies.
Sandin et al. (2014). JAMA 311, 1770–1777.
Risk-Reduction Surgery in Women with BRCA1
or BRCA2 Mutations
In a recent analysis of data from an international registry of
women with BRCA1 or BRCA2 mutations, the Hereditary
Ovarian Cancer Clinical Study Group further illustrates
the benefit of prophylactic oophorectomy in these
women. The study included more than 5,000 mutation
carriers who were followed for a mean of 5.6 years. Preven-
tive removal of the ovaries resulted in an 80% reduction in
risk of ovarian, peritoneal, or fallopian tube cancers, but it
also resulted in a 77% reduction in risk of all-cause mor-
tality. The authors use their data to provide guidance on
the age at which the surgery should be recommended in
women with BRCA1 or BRCA2mutations, and on the basis
of 18 occult fallopian tube cancers identified in women at
the time of prophylactic surgery, they also argue for the
removal of the fallopian tubes during the same surgery.
Finch et al. (2014). J. Clin. Oncol. 32, 1547–1553.
One Fell Swoop
The gene-by-gene approach or testing panels: which to
use? Both strategies are now available for genetic testing
of many heterogeneous conditions. One is tried and true,
and the other gives you more bang for your buck.
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The Amcess for ordering physicians, Ambry Genetics has recently
published its experience with four different hereditary can-
cer genetic testing panels of more than 2,000 patients. The
fraction of cases considered positive ranged from 7.2% to
9.6% depending on the panel. In contrast, the fraction of
cases with an inconclusive result ranged from 15.1% to
25.6%, and for the ovarian cancer panel, it was more
than three times that of the positive rate for the same
test. Not all genes on each panel conferred the same level
of cancer risk. For both the overall cancer panel and the
breast cancer panel, the genes in which pathogenic vari-
ants were most likely to be found were those such as
CHEK2 and PALB2, genes that appear to contribute a mod-
erate increase in cancer risk and for which management
guidelines for carriers and their families do not exist.
Although not unexpected, these results illustrate some of
the benefits and challenges of testing cancer-associated
genes in one fell swoop.
LaDuca et al. (2014). Genet. Med. Published online April 24,
2014. http://dx.doi.org/10.1038/gim.2014.40.
Getting It Right
When interpreting sequence variation, we don’t always get
it right, despite our best efforts. Unfortunately, once these
incorrect interpretations make it into databases and into
the literature, they are propagated, often yielding false-pos-
itive results in which genes and individual variants are
wrongly assumed to be causative for disease. When diag-
nostic labs, patients, and physicians use this information,
there is the potential for harm. An expert working group
assembled by the National HumanGenome Research Insti-
tute provides their perspective on these issues in a recent
Nature paper. They present their views on the types of evi-
dence needed for concluding that a gene is relevant for a
phenotype and those that are needed for interpreting a
specific variant within a causative gene. At both the gene
and variant levels, this working group argues for a more
quantitative approach to sequence interpretation.
MacArthur et al. (2014). Nature 508, 469–476.
Reversal of Fortune
One of the common causes of mortality in individuals with
the progressive disorder Friedreich ataxia (FA) is cardiomy-
opathy. Because adeno-associated virus (AAV) targets
the heart when injected intravenously, Perdomini et al.
wondered whether a gene therapy delivered via this routeta, GA 30322, USA
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could change the course of the disease. In fact, it not only
prevents cardiomyopathy in mice that are treated pre-
symptomatically but also can reverse damage in mice
that already have heart failure. Themodel they used lacked
frataxin in the cardiac and skeletal muscle and caused a
rapid and severe progression of cardiomyopathy, resulting
in death at approximately 9 weeks of age. Injecting these
mice at 3 weeks of age with an AAV-expressing human fra-
taxin prevented development of cardiac disease and re-804 The American Journal of Human Genetics 94, 803–804, June 5, 2sulted in normal survival rates. Even more strikingly,
when the gene therapy was delayed and given to mice
with advanced cardiac insufficiency, the treatment reversed
much of the heart damage, yielding rapid improvement in
cardiac function and mitochondrial organization and pro-
longing survival. Although this vector didn’t target all tis-
sues affected by FA, the change in disease course in the
mouse model is promising for future clinical trials.
Perdomini et al. (2014). Nat. Med. 20, 542–547.This Month in Our Sister JournalsfastSTRUCTURE
One of the popular algorithms for identifying clusters of
individuals on the basis of multilocus genotype infor-
mation is STRUCTURE. This can be used, for example,
for better understanding human population history and
ferretting out population structure, which can be a prob-
lem for genome-wide association studies. As samples get
bigger and our capacity for higher-throughput geno-
typing increases, the computational burden on methodssuch as STRUCTURE gets to be a problem. Raj, Stephens,
and Pritchard have developed an efficient algorithm
called fastSTRUCTURE, which uses a variational Bayesian
framework. It is almost 1003 faster than STRUCTURE
and is able to infer ancestry with accuracy similar
to that of other popular approaches to identifying popu-
lation structure.
Raj et al. (2014). Genetics. Published online April 15, 2014.
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